Alercell adds Harvard surgeon Paul Dreschnack to advisory board

By AI, Created 5:21 AM UTC, June 01, 2026, /AGP/ – Alercell named Paul A. Dreschnack, MD, to its advisory board on June 2, 2026, adding a microsurgeon and regenerative medicine investigator to guide clinical translation of its LENA platform for pre-symptomatic blood cancer detection. The appointment comes as the Montana company advances its LDT and FDA De Novo strategy and expands its precision oncology roadmap.

Why it matters: - Alercell is adding surgical and regenerative-medicine expertise to help move the LENA Platform from diagnostics research toward clinical use. - Paul A. Dreschnack’s background in microsurgery, pilot safety studies, and humanitarian surgery is directly relevant to the company’s plan to translate blood-cancer detection into patient care. - The appointment also supports Alercell’s broader regulatory and clinical strategy for LENA and the planned LENA-Rx therapeutic recommendation engine.

What happened: - Alercell announced on June 2, 2026, that it appointed Paul A. Dreschnack, MD, to its Advisory Board. - Dreschnack is a New York-based plastic, hand, and microsurgeon in private practice in Manhattan. - Alercell described Dreschnack as a Harvard-trained surgeon, a regenerative medicine investigator, and a four-time Nobel Peace Prize nominee. - Frederic Scheer, Alercell’s founder, chairman, CEO and chief scientific officer, said Dreschnack will help sharpen the clinical translation of LENA across the company’s Rocky Mountain expansion.

The details: - Dreschnack has authored multiple peer-reviewed pilot safety studies on extracellular vesicle and stem cell-based interventions. - His published work includes a 2023 BMC Neurology pilot study on extracellular vesicles in Bell’s palsy, plus follow-up case reports in regenerative medicine. - Alercell said Dreschnack’s experience in pilot study design aligns with the analytical-validity, clinical-validity and clinical-utility framework used for novel diagnostics and therapeutics. - The company said that experience is relevant to its laboratory-developed test and FDA De Novo strategy under Montana SB 535. - Dreschnack’s microsurgical background is intended to inform tissue diagnostics, biopsy workflows and surgeon-pathology coordination for the Alercell Precision Oncology Clinic. - Alercell also highlighted his 19-year leadership role with The India Project, a pediatric surgical charity that has delivered about 300,000 free corrective surgeries for congenital defects. - Dreschnack said detecting leukemia before clinical presentation could change which patients need treatment and when. - He said he joined the board because the science is rigorous, the regulatory strategy is disciplined and the team is committed to doing the work carefully.

Between the lines: - Alercell is signaling that its next stage is not just technical validation, but clinical integration and regulatory positioning. - Bringing in a surgeon with experience in first-in-human pilot studies suggests the company wants outside expertise on how to translate a diagnostics platform into real-world oncology workflows. - The emphasis on humanitarian work and public-service honors also frames the appointment as part credibility, part mission alignment.

What’s next: - Alercell said Dr. Dreschnack will help inform the clinical translation of the LENA Platform and the design of LENA-Rx. - The company is continuing its active Series A fundraising. - Alercell is also pursuing its two-rail regulatory strategy: LDT deployment through a clinical partner and an FDA De Novo pathway for LENA-Rx. - The company said the LENA Platform remains investigational and has not been cleared or approved by the U.S. Food and Drug Administration.

The bottom line: - Alercell is building advisory muscle around the hardest part of its plan: turning an AI-driven epigenetic diagnostics platform into something clinicians can use in practice.